Mobia Medical Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.00 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $9.03Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $300.6M Shares Outstanding 33.3M diluted Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Mobia Medical Inc. (formerly MicroTransponder, Inc.) is a commercial-stage medical device company pioneering chronic stroke recovery with its flagship Vivistim Paired Vagus Nerve Stimulation (VNS) System. As the first and only FDA-approved implantable solution for chronic ischemic stroke survivors with moderate-to-severe upper extremity impairments, Vivistim addresses a massive, untapped market of over 9 million stroke survivors in the US. Following its successful $150 million IPO in May 2026, Mobia has eliminated going-concern risks, converted its debt, and secured a robust cash runway to aggressively expand its direct sales force and establish Vivistim as the standard of care. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$15.00 Mean target$17.25 High · most bullish analyst$19.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $15.0015% Commercial adoption is slowed by reimbursement friction or high out-of-pocket costs during the transitional CMS payment classification phase. Widening operating losses and high cash burn from scaling the direct sales force force the company to seek dilutive secondary offerings before achieving self-sustainability. Base CaseCentral scenario $17.2560% Matches the consensus meanSteady commercial execution with revenue growing in line with consensus estimates (~$53.5M in FY 2026 and ~$78.15M in FY 2027). The company successfully utilizes its $134.5M net IPO proceeds to fund operations, expand its commercial footprint, and navigate the 2-3 year claims data collection period required for permanent CMS reimbursement classification. Bull CaseUpside scenario $19.0025% Rapid commercial adoption driven by direct sales force expansion and strong clinical validation (including published 2-year VNS-REHAB durability data) leads to faster-than-expected penetration of the ~1,500 US stroke centers. CMS permanently codifies the New Technology APC 1580 outpatient payment rate of ~$45,000, driving high-margin recurring revenue and accelerating the path to profitability. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |